ATE292615T1 - Inhibitoren der durch alpha 4 vermittelten zelladhäsion - Google Patents
Inhibitoren der durch alpha 4 vermittelten zelladhäsionInfo
- Publication number
- ATE292615T1 ATE292615T1 AT01966246T AT01966246T ATE292615T1 AT E292615 T1 ATE292615 T1 AT E292615T1 AT 01966246 T AT01966246 T AT 01966246T AT 01966246 T AT01966246 T AT 01966246T AT E292615 T1 ATE292615 T1 AT E292615T1
- Authority
- AT
- Austria
- Prior art keywords
- inhibitors
- alpha
- cell adhesion
- mediated cell
- mediated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22912800P | 2000-08-31 | 2000-08-31 | |
| PCT/US2001/026594 WO2002018320A2 (en) | 2000-08-31 | 2001-08-27 | INHIBITORS OF α4 MEDIATED CELL ADHESION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE292615T1 true ATE292615T1 (de) | 2005-04-15 |
Family
ID=22859926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01966246T ATE292615T1 (de) | 2000-08-31 | 2001-08-27 | Inhibitoren der durch alpha 4 vermittelten zelladhäsion |
Country Status (28)
| Country | Link |
|---|---|
| US (6) | US7026501B2 (enExample) |
| EP (1) | EP1315694B1 (enExample) |
| JP (1) | JP3899022B2 (enExample) |
| KR (1) | KR100528049B1 (enExample) |
| CN (1) | CN1229334C (enExample) |
| AR (1) | AR034556A1 (enExample) |
| AT (1) | ATE292615T1 (enExample) |
| AU (2) | AU8677801A (enExample) |
| BR (1) | BR0113629A (enExample) |
| CA (1) | CA2418054C (enExample) |
| CZ (1) | CZ303460B6 (enExample) |
| DE (1) | DE60109943T2 (enExample) |
| DK (1) | DK1315694T3 (enExample) |
| ES (1) | ES2240509T3 (enExample) |
| HK (1) | HK1052684B (enExample) |
| HU (1) | HUP0302693A3 (enExample) |
| IL (2) | IL154305A0 (enExample) |
| MX (1) | MXPA03001837A (enExample) |
| MY (1) | MY129000A (enExample) |
| NO (1) | NO327861B1 (enExample) |
| NZ (1) | NZ524043A (enExample) |
| PL (1) | PL206656B1 (enExample) |
| PT (1) | PT1315694E (enExample) |
| RU (1) | RU2250895C2 (enExample) |
| SI (1) | SI1315694T1 (enExample) |
| TW (1) | TWI224587B (enExample) |
| WO (1) | WO2002018320A2 (enExample) |
| ZA (1) | ZA200301039B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1325480C (zh) | 2000-08-18 | 2007-07-11 | 味之素株式会社 | 苯基丙氨酸衍生物 |
| TWI312347B (en) | 2001-02-08 | 2009-07-21 | Eisai R&D Man Co Ltd | Bicyclic nitrogen-containing condensed ring compounds |
| RU2308457C2 (ru) | 2001-04-27 | 2007-10-20 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Пиразоло [1, 5-а] пиридины и содержащие их лекарственные средства |
| MY140707A (en) * | 2002-02-28 | 2010-01-15 | Mitsubishi Tanabe Pharma Corp | Process for preparing a phenylalanine derivative and intermediates thereof |
| CN1703395A (zh) * | 2002-08-09 | 2005-11-30 | 特兰斯泰克制药公司 | 芳基和杂芳基化合物以及调节凝血的方法 |
| US7176216B2 (en) | 2002-10-22 | 2007-02-13 | Eisai Co., Ltd. | 7-phenylpyrazolopyridine compounds |
| TWI283679B (en) * | 2002-10-22 | 2007-07-11 | Eisai Co Ltd | 7-phenylpyrazolopyridine compounds |
| CA2531796A1 (en) * | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7501538B2 (en) | 2003-08-08 | 2009-03-10 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
| KR20110098980A (ko) | 2003-12-22 | 2011-09-02 | 아지노모토 가부시키가이샤 | 신규한 페닐알라닌 유도체 |
| US7410971B2 (en) | 2003-12-26 | 2008-08-12 | Eisai R&D Management Co., Ltd. | 1,2-di(cyclic)substituted benzene compounds |
| MY140489A (en) | 2003-12-26 | 2009-12-31 | Eisai R&D Man Co Ltd | 1,2-di (cyclic) substituted benzene compounds |
| US7419666B1 (en) | 2004-02-23 | 2008-09-02 | Massachusetts Eye And Ear Infirmary | Treatment of ocular disorders |
| EP1832580A4 (en) | 2004-12-20 | 2009-03-11 | Eisai R&D Man Co Ltd | 1-CYCLOPROPYLMETHYL-4-Ý2- (3,3,5,5) -TETRAMETHYLCYCLOHEXYL) PHENYL PIPERAZINE CRYSTAL AND SALT |
| BRPI0611243A2 (pt) | 2005-06-09 | 2010-08-24 | Ucb Pharma Sa | composto, enanciâmeros, diastereoisâmeros do mesmo ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto |
| EP2091916A2 (en) * | 2005-11-23 | 2009-08-26 | AstraZeneca AB | L-phenylalanine derivatives and their use as integrin antagonists |
| US7855291B2 (en) | 2005-12-29 | 2010-12-21 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
| CN103265495B (zh) * | 2005-12-29 | 2016-11-16 | 莱西肯医药有限公司 | 多环氨基酸衍生物及其使用方法 |
| US7897763B2 (en) | 2005-12-29 | 2011-03-01 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
| IL172896A0 (en) * | 2005-12-29 | 2006-06-11 | Yeda Res & Dev | Cxcr4 inhibition |
| WO2007092471A2 (en) * | 2006-02-03 | 2007-08-16 | The Regents Of The University Of California | Methods for inhibition of lymphangiogenesis and tumor metastasis |
| WO2007091046A1 (en) * | 2006-02-09 | 2007-08-16 | Astrazeneca Ab | Chemical compounds |
| US8410115B2 (en) * | 2006-02-28 | 2013-04-02 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds |
| LT2676967T (lt) | 2006-02-28 | 2019-09-10 | Biogen Ma Inc. | Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu |
| AU2007224228B2 (en) | 2006-03-03 | 2013-09-19 | Biogen Ma Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
| RU2493156C2 (ru) * | 2007-08-24 | 2013-09-20 | Лексикон Фармасьютикалз, Инк. | Способы получения соединений на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина |
| BRPI0911659B8 (pt) | 2008-04-15 | 2021-05-25 | Eisai R&D Man Co Ltd | composto 3-fenilpirazolo[5,1-b]tiazol e composição farmacêutica compreendendo o mesmo |
| AR078521A1 (es) | 2009-10-08 | 2011-11-16 | Eisai R&D Man Co Ltd | Compuesto pirazolotiazol |
| EP2491006A1 (en) * | 2009-10-21 | 2012-08-29 | Glaxo Group Limited | Process for preparing a phenylalanine derivative |
| SMT202500065T1 (it) | 2010-01-11 | 2025-03-12 | Biogen Ma Inc | Saggio per anticorpi del virus jc |
| US11287423B2 (en) | 2010-01-11 | 2022-03-29 | Biogen Ma Inc. | Assay for JC virus antibodies |
| KR102292563B1 (ko) | 2011-05-31 | 2021-08-24 | 바이오젠 엠에이 인코포레이티드 | Pml의 위험을 판단하는 방법 |
| WO2013126595A1 (en) * | 2012-02-21 | 2013-08-29 | Massachusetts Eye And Ear Infirmary | Methods for treating corneal and conjunctival inflammation and inflammatory disorders |
| WO2014193804A1 (en) | 2013-05-28 | 2014-12-04 | Biogen Idec Ma Inc. | Method of assessing risk of pml |
| WO2018085552A1 (en) * | 2016-11-02 | 2018-05-11 | Saint Louis University | Integrin antagonists |
| JP7189369B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４β７インテグリンの阻害のための化合物 |
| EP3873900B1 (en) | 2018-10-30 | 2025-01-08 | Gilead Sciences, Inc. | Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| HUE070112T2 (hu) | 2018-10-30 | 2025-05-28 | Gilead Sciences Inc | 3-(Kinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-dion-származékok mint alpha4beta7 integrin gátlók gyulladásos betegségek kezelésére |
| CN112996786B (zh) | 2018-10-30 | 2024-08-20 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
| JP7491996B2 (ja) | 2019-08-14 | 2024-05-28 | ギリアード サイエンシーズ， インコーポレイテッド | α４β７インテグリンの阻害のための化合物 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK148576A (da) | 1975-04-18 | 1976-10-19 | Boehringer Mannheim Gmbh | Fenylalkankarbonsyrederivater og fremgangsmade til deres fremstilling |
| BR9407933A (pt) | 1993-11-01 | 1996-11-26 | Japat Ltd | Antagonistas de receptores de endotelina |
| MX9604368A (es) | 1994-03-28 | 1997-12-31 | Ciba Geigy Japan Ltd | Antagonistas de receptores de endotelina. |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| AU5687396A (en) | 1995-04-21 | 1996-11-07 | Novarits Ag | N-aroylamino acid amides as endothelin inhibitors |
| CA2291762A1 (en) | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Biarylalkanoic acids as cell adhesion inhibitors |
| JP2002512625A (ja) | 1997-05-29 | 2002-04-23 | メルク エンド カンパニー インコーポレーテッド | 細胞接着阻害薬としての複素環アミド化合物 |
| CA2291708A1 (en) | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Sulfonamides as cell adhesion inhibitors |
| JP2002501518A (ja) | 1997-05-30 | 2002-01-15 | セルテック セラピューティックス リミテッド | 抗炎症性チロシン誘導体 |
| ATE249421T1 (de) | 1997-06-23 | 2003-09-15 | Tanabe Seiyaku Co | Inhibitoren der alpha4-beta1 vermittelten zelladhäsion |
| EP1001972A1 (en) | 1997-07-31 | 2000-05-24 | Elan Pharmaceuticals, Inc. | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| HUP0004529A3 (en) | 1997-07-31 | 2001-05-28 | American Home Prod | Sulfonilated dipeptide-compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use |
| AR016133A1 (es) | 1997-07-31 | 2001-06-20 | Wyeth Corp | Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria |
| KR20010022414A (ko) | 1997-07-31 | 2001-03-15 | 진 엠. 듀발 | Ｖｌａ-4에 의해 매개되는 백혈구 부착을 억제시키는4-아미노-페닐알라닌형 화합물 |
| JP2001512138A (ja) | 1997-07-31 | 2001-08-21 | エラン・ファーマシューティカルズ・インコーポレーテッド | Ｖｌａ−４が介在する白血球付着を阻害するベンジル化合物 |
| HUP0002682A3 (en) | 1997-07-31 | 2001-12-28 | American Home Products Corp Ma | Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4 |
| WO1999006432A1 (en) | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals, Inc. | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4 |
| PL338457A1 (en) | 1997-07-31 | 2000-11-06 | Elan Pharm Inc | Sulphonylated dipeptidic compounds capable to inhibit adhesion of leucocytes through the mediation of vla-4 |
| CN100369888C (zh) | 1997-08-22 | 2008-02-20 | 霍夫曼-拉罗奇有限公司 | 芳酰基苯丙氨酸衍生物 |
| KR100615760B1 (ko) | 1997-08-22 | 2006-08-25 | 에프. 호프만-라 로슈 아게 | 엔-알카노일페닐알라닌 유도체 |
| US6191171B1 (en) * | 1997-11-20 | 2001-02-20 | Merck & Co., Inc. | Para-aminomethylaryl carboxamide derivatives |
| AU1463499A (en) | 1997-11-21 | 1999-06-15 | Merck & Co., Inc. | Substituted pyrrole derivatives as cell adhesion inhibitors |
| EP1034164B1 (en) | 1997-11-24 | 2004-05-19 | Merck & Co., Inc. | Substituted beta-alanine derivatives as cell adhesion inhibitors |
| EP1033983A1 (en) | 1997-11-24 | 2000-09-13 | Merck & Co., Inc. | Cyclic amino acid derivatives as cell adhesion inhibitors |
| US6197794B1 (en) | 1998-01-08 | 2001-03-06 | Celltech Therapeutics Limited | Phenylalanine derivatives |
| MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
| ES2226413T3 (es) * | 1998-02-26 | 2005-03-16 | Celltech Therapeutics Limited | Derivados de fenilalanina como inhibidores de alfa-4 integrinas. |
| US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
| GB9811159D0 (en) | 1998-05-22 | 1998-07-22 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9812088D0 (en) | 1998-06-05 | 1998-08-05 | Celltech Therapeutics Ltd | Chemical compounds |
| AU8059598A (en) | 1998-06-11 | 1999-12-30 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
| TW591026B (en) | 1998-06-23 | 2004-06-11 | Upjohn Co | Inhibitors of alpha4beta1 mediated cell adhesion |
| JP2003524614A (ja) | 1998-12-22 | 2003-08-19 | 田辺製薬株式会社 | α４β１媒介細胞接着のインヒビター |
| GB2354440A (en) | 1999-07-20 | 2001-03-28 | Merck & Co Inc | Aryl amides as cell adhesion inhibitors |
| WO2001012183A1 (en) * | 1999-08-16 | 2001-02-22 | Merck & Co., Inc. | Heterocycle amides as cell adhesion inhibitors |
| WO2001014328A2 (en) * | 1999-08-20 | 2001-03-01 | Merck & Co., Inc. | Substituted ureas as cell adhesion inhibitors |
| JP2003509488A (ja) * | 1999-09-24 | 2003-03-11 | ジェネンテック・インコーポレーテッド | チロシン誘導体 |
| WO2002018329A1 (en) | 2000-08-31 | 2002-03-07 | Eli Lilly And Company | Acetylenic sulfonamide derivatives |
-
2001
- 2001-08-21 MY MYPI20013917A patent/MY129000A/en unknown
- 2001-08-27 EP EP01966246A patent/EP1315694B1/en not_active Expired - Lifetime
- 2001-08-27 KR KR10-2003-7001993A patent/KR100528049B1/ko not_active Expired - Fee Related
- 2001-08-27 HK HK03105043.3A patent/HK1052684B/en not_active IP Right Cessation
- 2001-08-27 AU AU8677801A patent/AU8677801A/xx active Pending
- 2001-08-27 CA CA 2418054 patent/CA2418054C/en not_active Expired - Fee Related
- 2001-08-27 WO PCT/US2001/026594 patent/WO2002018320A2/en not_active Ceased
- 2001-08-27 ES ES01966246T patent/ES2240509T3/es not_active Expired - Lifetime
- 2001-08-27 RU RU2003105885/04A patent/RU2250895C2/ru not_active IP Right Cessation
- 2001-08-27 AT AT01966246T patent/ATE292615T1/de active
- 2001-08-27 ZA ZA200301039A patent/ZA200301039B/xx unknown
- 2001-08-27 DK DK01966246T patent/DK1315694T3/da active
- 2001-08-27 CN CNB018149871A patent/CN1229334C/zh not_active Expired - Fee Related
- 2001-08-27 US US10/333,985 patent/US7026501B2/en not_active Expired - Fee Related
- 2001-08-27 AU AU2001286778A patent/AU2001286778B2/en not_active Ceased
- 2001-08-27 HU HU0302693A patent/HUP0302693A3/hu unknown
- 2001-08-27 SI SI200130351T patent/SI1315694T1/xx unknown
- 2001-08-27 PL PL365668A patent/PL206656B1/pl unknown
- 2001-08-27 JP JP2002523438A patent/JP3899022B2/ja not_active Expired - Fee Related
- 2001-08-27 MX MXPA03001837A patent/MXPA03001837A/es active IP Right Grant
- 2001-08-27 NZ NZ524043A patent/NZ524043A/en not_active IP Right Cessation
- 2001-08-27 DE DE60109943T patent/DE60109943T2/de not_active Expired - Lifetime
- 2001-08-27 IL IL15430501A patent/IL154305A0/xx unknown
- 2001-08-27 BR BR0113629-1A patent/BR0113629A/pt active Search and Examination
- 2001-08-27 PT PT01966246T patent/PT1315694E/pt unknown
- 2001-08-27 CZ CZ20030487A patent/CZ303460B6/cs not_active IP Right Cessation
- 2001-08-31 AR ARP010104172A patent/AR034556A1/es active IP Right Grant
- 2001-08-31 TW TW090121581A patent/TWI224587B/zh not_active IP Right Cessation
-
2003
- 2003-02-05 IL IL154305A patent/IL154305A/en not_active IP Right Cessation
- 2003-02-25 NO NO20030885A patent/NO327861B1/no not_active IP Right Cessation
-
2005
- 2005-07-13 US US11/179,729 patent/US7456217B2/en not_active Expired - Fee Related
-
2008
- 2008-10-07 US US12/247,129 patent/US7671090B2/en not_active Expired - Fee Related
-
2010
- 2010-01-07 US US12/683,648 patent/US7872151B2/en not_active Expired - Fee Related
- 2010-12-08 US US12/962,707 patent/US8501809B2/en not_active Expired - Fee Related
-
2013
- 2013-07-03 US US13/934,405 patent/US20130289109A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE292615T1 (de) | Inhibitoren der durch alpha 4 vermittelten zelladhäsion | |
| DK1049662T3 (da) | Inhibitorer af alpha4-medieret celleadhæsion | |
| DK0842944T3 (da) | Heterocycler som inhibitorer af leukocytadhæsionen og som antagonister af VLA-4 | |
| DK0842945T3 (da) | Heterocykliske forbindelser som inhibitorer af leukocytadhæsionen og VLA-4-antagonister | |
| EP1507541A4 (en) | HEMMER AND APPLICATION METHOD THEREFOR | |
| EP1496894A4 (en) | ANGIOGENESIS INHIBITORS | |
| DK0842943T3 (da) | 5-Ring-heterocykliske forbindelser som inhibitorer af leukocytadhæsion og som VLA-4-antagonister | |
| DE60317564D1 (de) | Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten | |
| NO20003808L (no) | Substituerte oksoazaheterosyklylfaktor Xa inhibitorer | |
| DK1064298T3 (da) | Inhibitorer af caspaser | |
| DK0923585T3 (da) | Phosphinatbaserede inhibitorer af matrixmetalloproteinaser | |
| DK1077943T3 (da) | Heterocykliske inhibitorer af p38 | |
| ID19198A (id) | Inhibitor metaloprotease heterosiklik | |
| DK1114051T3 (da) | Inhibitorer for p38 | |
| IS7792A (is) | Hýdantóínafleiður og notkun þeirra sem TACE hemla | |
| DE69942123D1 (de) | FACTOR VIIa INHIBITORE | |
| ID18416A (id) | Inhibitor metaloprotease diheterosiklik | |
| EP1691812A4 (en) | GTPASE INHIBITORS AND METHOD OF USE | |
| IS5302A (is) | Nýjar amidínóafleiður og notkun þeirra sem þrombínhemla | |
| EP1587485A4 (en) | OIL RUBBER TOPICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
| PT1189929E (pt) | Inibidores do factor viia | |
| ATE411995T1 (de) | Inhibitoren der alpha-l-beta-2- integrinvermittelten zelladhäsion | |
| DK1130214T3 (da) | Korrosionsinhibitorer | |
| NO20013669D0 (no) | Reverse hydroksamatinhibitorer av matriks metalloproteinaser | |
| EP1222308A4 (en) | INHIBITORS OF HISTONE ACETYL ANTIPROTOZOA TRANSFERASE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1315694 Country of ref document: EP |